Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

Clinically important improvements in cardiovascular risk factors and adverse cardiovascular, heart failure and renal outcomes have been observed in numerous cardiovascular outcome trials (CVOTs) investigating the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors over the last 5 years. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, David M., Nawaz, Asif, Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843788/
https://www.ncbi.nlm.nih.gov/pubmed/33185854
http://dx.doi.org/10.1007/s13300-020-00951-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843788/
https://www.ncbi.nlm.nih.gov/pubmed/33185854
http://dx.doi.org/10.1007/s13300-020-00951-6

Ejemplares similares